Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes.

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Abstract Text:

Gennady Bratslavsky,Jack J Liu,Aaron D Johnson,Sunil Sudarshan,Peter L Choyke,W Marston Linehan,Peter A Pinto,Gennady Bratslavsky,Jack J Liu,Aaron D Johnson,Sunil Sudarshan,Peter L Choyke,W Marston Linehan,Peter A Pinto,Gennady Bratslavsky,Jack J Liu,Aaron D Johnson,Sunil Sudarshan,Peter L Choyke,W Marston Linehan,Peter A Pinto,

PURPOSE: Patients with von Hippel-Lindau disease may require repeat partial nephrectomies to avoid the need for renal replacement therapy. We evaluated outcomes in patients who underwent third or fourth partial nephrectomies on the same kidney, which we call salvage partial nephrectomy. MATERIALS AND METHODS: We retrospectively reviewed the charts of patients who underwent surgery at the National Cancer Institute from 1999 to 2006. We identified 11 of 13 patients in whom salvage partial nephrectomy was performed. Surgical outcomes were assessed by renal preservation as well as intraoperative and postoperative complications. Functional outcomes were assessed by comparing serum creatinine, 24-hour urine creatinine clearance, and nuclear renal scan before and after salvage partial nephrectomy. RESULTS: All patients were alive and had no radiographic evidence of metastatic disease at a median followup of 25 months (range 3 to 83). Major perioperative complications occurred in 6 of 13 patients (46%) and loss of a renal unit occurred in 3 (23%). None of the patients in whom renal units were preserved required dialysis, although there was an upward trend in serum creatinine and a downward trend in creatinine clearance at postoperative followup (p = 0.07 and 0.08, respectively). CONCLUSIONS: Although salvage partial nephrectomy is technically demanding and it has a high complication rate, it allows many patients to avoid dialysis. We believe that this experience can be used as a reference for surgeons and patients when considering the risks and benefits of salvage partial nephrectomy.

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Publishing Authors By Initials

G Bratslavsky,JJ Liu,AD Johnson,S Sudarshan,PL Choyke,WM Linehan,PA Pinto,G Bratslavsky,JJ Liu,AD Johnson,S Sudarshan,PL Choyke,WM Linehan,PA Pinto,G Bratslavsky,JJ Liu,AD Johnson,S Sudarshan,PL Choyke,WM Linehan,PA Pinto,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of urology

VOLUME: 179

Page Numbers: 67-70

Journal Abbreviation: J. Urol.

ISSN: 1527-3792

DAY: 13

MONTH: 11

YEAR: 2007

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376374

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes.

AFFILIATION: Urologic Oncology Branch and Molecular Imaging Program (PLC), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Urol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes Related Publications

• "Being transformed by illness": adolescents' diabetes experience.
• 'It's really a hard life': love, gender and HIV risk among male-to-female transgender persons.
• A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36.
• A papillary fibroelastoma of the tricuspid valve.
• Biologically based complementary and alternative medicine use among breast cancer survivors: relationship to dietary fat consumption and exercise.
• Cancer-related beliefs and health behavior change among breast cancer survivors and their first-degree relatives.
• Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
• Drug eluting stents for ST-elevation myocardial infarction: risk and benefit.
• Evaluating measurement uncertainty in the microbiological assay of vancomycin from methodology validation data.
• Human papillomavirus in oral squamous cells carcinoma in a population of 75 Brazilian patients.
• Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy.
• Pasteurella meningo-encephalitis--a risk of household pets.
• Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women.
• Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population.
• Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes.
• Synthesis of aza- and thia-spiroheterocycles and attempted synthesis of spiro sulfonium compounds related to salacinol.
• The founder of a key European association. Interview by Ingrid Torjesen.
• Validation of erythromycin microbiological assay using an alternative experimental design.
• [Alberto's victory over ALS (amyotrophic lateral sclerosis): defense mechanism vs coping strategies]
• [Feeding disorders in children with gastro-esophageal reflux disease]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [What is an efficient health technology in Spain?]